Trading Statement

Byotrol PLC
18 April 2007



                                  BYOTROL PLC



               UPDATE ON TRADING AND RESULTS OF INDEPENDENT TRIAL



The Directors of Byotrol plc (the 'Company') are pleased to be able to provide
an update on the recent strong progress made across the group following the end
of its financial year to 31 March 2007 and to report that direct product sales
revenues will be in line with the Directors' expectations and in the last
quarter of the financial year £240,000 of sales orders were delivered.



The Company has made significant progress across all of its target markets in
the year to 31 March 2007 and has been successful in attracting a number of new
clients with global scale which the Directors believe will generate significant
new sales revenue to the Company.



Within the UK industrial medical sector Byotrol is pleased to be able to
announce it has recently shipped an order for more than 20,000 litres of Byotrol
concentrates which will be used in a speciality medical application.



The Company is also working on a number of new applications for Byotrol where
the Directors see significant opportunities for sale of Byotrol. By way of
example, a number of leading UK agricultural distributors have recently placed
orders with the Company for disinfectant and wipe products containing Byotrol's
technology. Similarly in the pet care niche, sales of a range of grooming
products containing Byotrol in leading retailer Pets at Home have significantly
exceeded projections and the product range was recently recognised as new
product of the year by Pets At Home



The Company's ongoing testing and validation programme has also made strong
progress and the Directors are pleased to be able to announce the publication of
a North American study detailing the positive effects of the Company's
Polysphere(R) product in battling multidrug-resistant organisms ('MDROs'). This
study has resulted in the participating hospital incorporating Byotrol products
into its cleaning regime and this represents a very encouraging step in
penetrating the US healthcare market.



The study, carried out by hospital based researchers at Monroe Hospital,
Bloomington, Indiana found that Polysphere(R) provided 'residual disinfecting
properties to surfaces that may become contaminated by MDROs' and that in
particular it was 'effective for up to three (consecutive) days post treatment'.



All surfaces were inoculated using Vancomycin Resistant Enterococcus faecalis ('
VRE') and Methicillin Resistant Staphylococcus Aureus ('MRSA'). The study found
that for three consecutive days no growth of VRE occurred and that growth of
MRSA was so sparse that it 'could be considered no growth'.



The full text of the paper can be found by following this link:



http://www.monroehospital.com/UserFiles/File/A_weapon_against_superbugs_2.pdf





Commenting on the recent successes Byotrol plc Chief Executive David McRobbie
said:



'These recent successes demonstrate our ability to commercialise an innovative
technology and generate future revenue streams across our target markets. '
Equally pleasing is the successful study within North America because this
validates our technology in another marketplace. Importantly the work at Monroe
Hospital demonstrates our ability to establish a trial that proves the efficacy
of our technology and to convert that into product sales in the highly demanding
US healthcare market.'



The preliminary results for the year ended 31 March 2007 are expected to be
announced in June 2007.



Enquiries:


Byotrol plc                                        0161 277 9518

Stephen Falder
Deputy Chairman



Richard Bell                                       07825 204110
Finance Director


Charles Stanley Securities                         020 7149 6457

Philip Davies

McCann Erickson PR                                 01625 822540

Jim Rothnie




                      This information is provided by RNS
            The company news service from the London Stock Exchange